Remotely Supervised tDCS+ for Complex Attention in mTBI (Cognetric)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Active tDCS and Cognitive Training Intervention, Sham tDCS and Cognitive Training Intervention.
- Who it may be relevant to
- Registry conditions: Brain Concussion, Brain Trauma, Attention Concentration Difficulty, Brain Injuries. Basic parameters: 18 years — 60 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Remotely Supervised tDCS Combined With Cognitive Training to Improve Complex Attention in Active Duty Service Members and Veterans With Mild TBI (Cognetric)
Overview
The proposed study will evaluate a new approach to cognitive rehabilitation of mTBI using a brain stimulation technique called "Remotely Supervised Transcranial Direct Current Stimulation combined with Cognitive Training" (RS-tDCS+) which has shown promise for improving complex attention in both healthy and clinical populations. RS-tDCS+ is a home-based, low-risk, non-invasive technique that is designed to boost cognitive training by enhancing learning and the brain's ability to reorganize connections. This study will evaluate RS-tDCS+ for improving complex attention in Active Duty Service Members (ADSM) and Veterans with a history of mTBI. Different tests of complex attention and symptom questionnaires will be used to determine the effects of real versus sham (placebo) RS-tDCS+. Second, the investigators will investigate electrical and connectivity changes in the brain associated with RS-tDCS+ using electroencephalogram (EEG) and magnetic resonance imaging (MRI). Third, the investigators will investigate the lasting effects of any observed changes by evaluating participants at 1 and 6 weeks post-treatment. Lastly, the investigators will explore the impact of individual differences (e.g., PTSD, depression, sleep quality, time since injury, baseline impairment, age, sex, ADSM versus Veteran) on treatment outcome.
Detailed description
Objectives:
Attention, concentration, and working memory (i.e., complex attention) deficits are the most reported neurocognitive sequelae of mild traumatic brain injury (mTBI) and have been associated with patterns of decreased neural activation. Existing cognitive rehabilitation interventions require significant time and effort and are limited by small-to-moderate effect sizes and uncertain durability/generalization of effects. Novel, neuroplasticity-based interventions that improve complex attention and can be administered remotely are needed to increase access to care, decrease recovery time, and improve outcomes and quality of life following mTBI. This multi-site study will investigate remotely-supervised tDCS (RS-tDCS) combined with cognitive training in the chronic phase of recovery (≥3 months) from mTBI to 1) increase accessibility to care, 2) improve cognitive functioning, post-concussion symptom outcomes, and quality of life and 3) investigate the durability of the intervention in Active Duty Service Members (ADSM; at the Naval Medical Center San Diego (NMCSD) and Veterans (at the Minneapolis VA Health care System (MVAHCS)).
Research Plan and Methods:
This is a double-blind, randomized, sham-controlled study. 80 Veterans from the MVAHCS and 80 ADSM from NMCSD (total N=160) will be recruited. Participants will have a history of mTBI and self-reported attention and/or concentration difficulties. Baseline assessment will include self-reported symptoms and objective neurocognitive performance. Resting state functional connectivity changes will be measured with functional magnetic resonance imaging (fMRI) and oscillatory brain activity will be measured with EEG, both collected at baseline and at post-intervention assessments. Participants will be randomized to either active RS-tDCS or sham RS-tDCS, using stratified randomization by baseline cognitive scores. The intervention sessions will occur in the participant's home, 10 sessions within 2 weeks. Two post-intervention assessments, mirroring the baseline assessment, will occur approximately 1 week and 6 weeks after the intervention. Additionally, the investigators will collect longitudinal real-time data, daily, on TBI symptoms, cognitive, and mood factors during the 6 weeks post-intervention using Ecological Momentary Assessment (EMA).
Clinical Relevance:
RS-tDCS+ addresses two major obstacles of current TBI treatments: Accessibility and adherence. RS-tDCS+ offers several benefits as it can be monitored remotely, and can be self-administered in the home after the first session. If RS-tDCS proves effective, this non-invasive intervention could dramatically improve access to a validated treatment that can be rapidly implemented within various DOD and VA settings to reduce TBI-related symptoms, improve cognition, enhance recovery, bolster occupational performance, and improve quality of life.
Interventions
- Combination product Active tDCS and Cognitive Training Intervention
Cognitive training will occur concurrently with active tDCS session. The cognitive training occurs on a computer and consists of 5 exercises specifically selected and scientifically supported to (i) place demands on the executive function system (e.g. working memory, behavioral inhibition, decision making, and set- shifting), (ii) adapt to challenge the participant's current ability level, (iii) provide ongoing feedback, and (iv) present novel stimuli across visual and auditory modalities During - Combination product Sham tDCS and Cognitive Training Intervention
Cognitive training will occur concurrently with sham tDCS session. The cognitive training occurs on a computer and consists of 5 exercises specifically selected and scientifically supported to (i) place demands on the executive function system (e.g. working memory, behavioral inhibition, decision making, and set- shifting), (ii) adapt to challenge the participant's current ability level, (iii) provide ongoing feedback, and (iv) present novel stimuli across visual and auditory modalities During e
Primary outcome measures
- Symbol Digit Modalities Test (SDMT) [Time frame: Baseline, 1-week post, & 6-weeks post intervention]
- Neuropsychological Assessment Battery (NAB) Attention Module [Time frame: Baseline, 1-week post, & 6-weeks post intervention]
- Neurobehavioral Symptom Inventory (NSI) [Time frame: Baseline, 1-week post, & 6-weeks post intervention]
- Electroencephalogram (EEG) - Resting State Functional Connectivity [Time frame: Baseline, 1-week post, & 6-weeks post intervention]
- Electroencephalogram (EEG) - Resting State Spectral Power [Time frame: Baseline, 1-week post, & 6-weeks post intervention]
- Magnetic Resonance Imaging (MRI) - T1 (optional) [Time frame: Baseline & 1-week post intervention]
- Magnetic Resonance Imaging (MRI) - T2 (optional) [Time frame: Baseline & 1-week post intervention]
- Magnetic Resonance Imaging (MRI) - T2* (optional) [Time frame: Baseline & 1-week post intervention]
- Magnetic Resonance Imaging (MRI) - DWI (optional) [Time frame: Baseline & 1-week post intervention]
- Magnetic Resonance Imaging (MRI) - ASL (optional) [Time frame: Baseline & 1-week post intervention]
Secondary outcome measures (2)
- BrainHQ Task Load Index (TLX) [Time frame: Collected during the Intervention block at sessions 1, 5, & 10 (b/t baseline & 1-week post)]
- Fusion Task Load Index (F-TLX) [Time frame: Baseline, 1-week post, & 6-weeks post intervention]
Eligibility criteria
Inclusion criteria
- Active-Duty Service Members.
- Ages 18 to 60.
- All genders.
- All racial and ethnic groups.
- History of mild TBI (as defined by the DOD/VA criteria used in conjunction with the OSU TBI-ID) sustained at least 3 months and no more than 10 years prior to enrollment.
- Self-reported attention and/or concentration difficulties.
- At least one cognitive symptom reported on the Neurobehavioral Symptom Inventory (NSI) cognitive subscale.
Exclusion criteria
- Presence of a medical, psychiatric, physical or non-physical disease, disorder, condition, injury, disability or pre-existent history such that study participation, in the opinion of the PI: (a) may pose a significant risk to the participant; (b) raises the possibility that the participant is unlikely to successfully complete all of the requirements of the study according to the study protocol; or (c) might adversely impact the integrity of the data or the validity of the study results. Specific conditions include (but are not limited to) a history of: brain tumor, epilepsy, cerebral vascular accident (CVA), Schizophrenia, Bipolar Disorder, and Mania.
- History of prior treatment with ECT or neuromodulation in the last 12 months.
- Current, diagnosed substance dependence.
- Newly prescribed medication within the previous 3 weeks.
- Diagnosis of intellectual disability or pervasive developmental disorder (i.e., premorbid IQ less than or equal to 70).
- Any medical condition or treatment other than mild TBI (e.g., stroke, tumor, HIV, moderate-severe TBI), with significant neurological disorder or insults that, based on the Principal Investigator's judgment, would impact risk.
- Psychosis or mania within 30 days of enrollment, as determined by the PI, based on a psychiatric history and examination and/or a review of available medical records
- Contraindications for tDCS (e.g., metallic cranial plates/screws or implanted device, eczema or skin lesions on scalp)
- A positive pregnancy report.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Triple blind
- Primary purpose
- Treatment
Study locations
United States · 2 centers
- Naval Medical Center San Diego — San Diego
- Minneapolis VA Health Case System — Minneapolis
Identifiers
NCT: NCT06413173 · NMCSD.2023.0048